Market Movers: Hims & Hers Health (HIMS) Jumps 5.28% to Close at $4.59 June 23

Equities Staff  |

Hims & Hers Health Inc - Class A (NYSE:HIMS) shares moved 5.28% today on 2,647,106 shares - compared to the 30 day average of 1,905,920 shares traded.

After closing today at $4.59 the company has a 50 day moving average of $3.83.

The company anticipates its next earnings on 2022-08-10.

Hims & Hers Health is down 33.44% so far this year.

For technical charts, analysis, and more on Hims & Hers Health visit the company profile.

About Hims & Hers Health Inc - Class A

Hims & Hers is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more. Launched in November 2017, the company also offers thoughtfully created and curated health and wellness products. With products and services available across all 50 states and Washington, D.C., Hims & Hers is able to provide all Americans access to quality, convenient and affordable care. Hims & Hers was founded by CEO Andrew Dudum, Hilary Coles, Jack Abraham and Joe Spector at venture studio Atomic in San Francisco, California.

To get more information on Hims & Hers Health Inc - Class A and to follow the company's latest updates, you can visit the company's profile page here: Hims & Hers Health Inc - Class A's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content